Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)
2006; Elsevier BV; Volume: 43; Issue: 1 Linguagem: Inglês
10.1016/j.ejca.2006.09.005
ISSN1879-0852
AutoresJ. Belderbos, Lon Uitterhoeve, Nico van Zandwijk, Huub Belderbos, Patrick Rodrigus, Paul van de Vaart, Allan Price, Nico van Walree, Cathérine Legrand, Sonia Dussenne, Harry Bartelink, Giuseppe Giaccone, Caro Koning,
Tópico(s)Hepatocellular Carcinoma Treatment and Prognosis
ResumoA randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients. Methods One hundred and fifty-eight patients were randomised to receive two courses of Gemcitabine (1250 mg/m2 days 1, 8) and Cisplatin (75 mg/m2 day 2) prior to, or daily low-dose Cisplatin (6 mg/m2) concurrent with radiotherapy, consisting of 24 fractions of 2.75 Gy in 32 days, with a total dose of 66 Gy. Results Acute haematological toxicity grade 3/4 was more pronounced in the sequential (S) (30% versus 6%), oesophagitis grade 3/4 more frequent in the concurrent (C) arm (5% versus 14%). Late oesophagitis grade 3 was 4% (S and C), pneumonitis grade 3/4 14% (S) and 18% (C). Because of the poor power of the study no significant differences in median survival (MS), overall survival (OS) and progression-free survival (PFS) could be detected. MS was 16.2 (S) and 16.5 (C) months, 2-year OS was 34% (S) and 39% (C), 3-year OS was 22% (S) and 34% (C). Conclusion Radiotherapy 66 Gy given concurrently with daily low-dose Cisplatin or after two courses of Gemcitabine/Cisplatin was well tolerated. Due to early closure no conclusions can be reached on the relative merits; both arms showed good OS.
Referência(s)